2017-03-15,New Publication Describes Positive Patient Experience In Study Of Ocular Therapeutix' DEXTENZA™ Following Cataract Surgery
2017-03-10,Ocular Therapeutix™ Reports Fourth Quarter And Full Year 2016 Financial Results
2017-03-08,Ocular Therapeutix™ To Report Fourth Quarter And Full Year 2016 Financial Results
2017-02-22,Ocular Therapeutix™ Announces FDA Acceptance Of NDA Resubmission For DEXTENZA™ For The Treatment Of Ocular Pain Occurring After Ophthalmic Surgery
2017-02-09,Ocular TherapeutixTM To Present At Three Upcoming Investor Conferences
2017-01-24,Relative Strength Alert For Ocular Therapeutix
2017-01-24,Ocular Therapeutix, Inc. Announces Pricing Of Public Offering Of Common Stock
2017-01-23,Ocular Therapeutix, Inc. Announces Public Offering Of Common Stock
2017-01-23,Ocular Therapeutix™ Resubmits NDA For DEXTENZA™ For The Treatment Of Ocular Pain Occurring After Ophthalmic Surgery
2017-01-04,Ocular Therapeutix™ Announces Additional Successful Results For Phase 3 Clinical Trial Of DEXTENZA™
2016-12-29,3 Small Biotechs With Insider Buying
2016-12-28,Ocular Therapeutix Stock Sees Short Interest Increase 16%
2016-11-14,Ocular Therapeutix™ Announces Successful Topline Results For Both Inflammation And Pain Primary Efficacy Endpoints From Phase 3 Clinical Trial Of DEXTENZA™
2016-11-10,Short Interest In Ocular Therapeutix Jumps 10.5%
2016-11-09,Ocular Therapeutix™ To Present At Two Upcoming Investor Conferences
2016-11-09,Ocular Therapeutix™ Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-11-02,Ocular Therapeutix™ To Hold Third Quarter 2016 Financial Results Conference Call On Wednesday, November 9, 2016
2016-10-20,Ocular Therapeutix™ Strengthens Management Team With The Appointment Of Andy Hurley As Chief Commercial Officer
2016-10-13,Ocular Therapeutix (OCUL) Stock Soars on Regeneron Deal
2016-10-13,Ocular Therapeutix™ Outlines Development Strategy For Its Sustained Release Intravitreal Depots To Address Serious Retinal Diseases
2016-10-13,Ocular Therapeutix™ And Regeneron Enter Into Strategic Collaboration To Develop Sustained Release Formulation Of Aflibercept For The Treatment Of Wet AMD And Other Serious Retinal Diseases
2016-10-04,Ocular Therapeutix™ Begins Enrollment In First Phase 3 Clinical Trial With OTX-TP (Sustained Release Travoprost) For The Treatment Of Glaucoma And Ocular Hypertension
2016-09-13,Lifshitz & Miller Law Firm Announces Investigation Of AECOM, American Farmland Company, Centene Corp., Cepheid, Cray Inc., Echo Global Logistics, Inc., Ocular Therapeutix, Inc., And Pure Storage, Inc.
2016-09-13,Short Interest Increases 16.4% For OCUL
2016-08-31,Ocular Therapeutix™ To Participate In The Morgan Stanley Global Healthcare Conference
2016-08-09,Today's Weak On High Volume Stock: Ocular Therapeutix (OCUL)
2016-08-09,Ocular Therapeutix™ Reports Second Quarter 2016 Financial Results And Provides Corporate Update
2016-08-05,These 7 Stocks Under $10 Are Making Big Moves Higher
2016-08-05,Ocular Therapeutix™ Announces Presentation At The Ophthalmology Innovation Summit (OIS) At The American Society Of Retina Specialists (ASRS)
2016-08-04,Ocular Therapeutix (OCL) Stock Soars, FDA: Corrective Actions Address Concerns
2016-08-03,Ocular Therapeutix™ Provides Update On NDA For DEXTENZA™ For The Treatment Of Post-Surgical Ocular Pain
2016-08-02,Ocular Therapeutix™ To Report Second Quarter 2016 Financial Results
2016-08-01,IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of Ocular Therapeutix, Inc. And Advises Investors With Losses To Contact The Firm
2016-07-27,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Regarding Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of Ocular Therapeutix Inc.
2016-07-25,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Ocular Therapeutix, Inc. (OCUL)
2016-07-25,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Ocular Therapeutix, Inc. - OCUL
2016-07-25,Ocular Therapeutix™ Receives Complete Response Letter From FDA For Its NDA For DEXTENZA™ For The Treatment Of Post-Surgical Ocular Pain
2016-07-13,Ocular Therapeutix Enters Oversold Territory (OCUL)
2016-07-12,Ocular Therapeutix (OCUL) Stock: Weak On High Volume Today
2016-07-06,Ocular Therapeutix™ To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference
2016-06-27,Ocular Therapeutix Stock Sees Short Interest Fall 17.3%
2016-06-06,Noteworthy Monday Option Activity: OCUL, MED, MGM
2016-06-06,Stocks at Session Highs as Crude Closes Near $50
2016-06-06,Why Ocular Therapeutix (OCUL) Stock Is Tanking Today
2016-06-06,Ocular Therapeutix is Now Oversold (OCUL)
2016-06-06,Stocks Hover Near Session Highs Ahead of Yellen Speech
2016-06-06,Stock Futures Inch Higher as Wall Street Awaits Yellen
2016-06-06,Ocular Therapeutix™ Announces Topline Results Of Second Phase 3 Clinical Trial Of DEXTENZA™ For The Treatment Of Allergic Conjunctivitis
2016-06-02,Ocular Therapeutix™ To Present At Two Upcoming Investor Conferences
2016-05-10,Ocular Therapeutix™ Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-05-03,Ocular Therapeutix™ To Report First Quarter 2016 Financial Results
2016-04-27,Ocular TherapeutixTM Completes End-of-Phase 2 Review With FDA For OTX-TP (Sustained Release Travoprost) For Glaucoma And Ocular Hypertension
2016-04-22,4 Biotech Stocks You Should Be Watching Right Now
2016-04-21,Commit To Purchase Ocular Therapeutix At $12.50, Earn 41.5% Annualized Using Options
2016-04-16,3 Biotech Stocks With Charts to Watch -- And One Bonus Stock!
2016-03-30,7 Stocks Under $10 to Trade for Breakout Gains
2016-03-28,Ocular TherapeutixTM To Host Investor Day On April 6, 2016
2016-03-18,These 7 Stocks Under $10 Are Set to Soar Higher
2016-03-10,Ocular TherapeutixTM Reports Fourth Quarter And Full Year 2015 Financial Results
2016-03-02,Ocular Therapeutix™ To Report Fourth Quarter And Full Year 2015 Financial Results
2016-02-18,Trade-Ideas: Ocular Therapeutix (OCUL) Is Today's Weak On High Relative Volume Stock
2016-02-18,Ocular TherapeutixTM To Present At Two Upcoming Investor Conferences
2016-02-17,One Reason Why Ocular (OCUL) Stock is Advancing Today
2016-02-16,Ocular Therapeutix™ Announces Phase 3 Clinical Development Plan For OTX-TP, An Innovative Therapy For Glaucoma And Ocular Hypertension
2016-02-12,Ocular Therapeutix is Now Oversold (OCUL)
2016-01-11,Ocular TherapeutixTM Strengthens Executive Management Team With The Appointment Of Highly Regarded Ophthalmologist Jonathan H. Talamo, M.D., As Chief Medical Officer
2015-12-18,4 Biotech Stocks Under $10 Poised for Big Breakouts
2015-12-14,Ocular Therapeutix™ Announces Encouraging Top-Line Results From Exploratory Phase 2 Trial For DEXTENZA™ In Patients With Inflammatory Dry Eye Disease
2015-12-09,Ocular Therapeutix™ Announces FDA Acceptance Of NDA Filing For DEXTENZA™ For The Treatment Of Post-Surgical Ocular Pain
2015-11-24,Ocular Therapeutix™ To Present At The Piper Jaffray 27th Annual Healthcare Conference
2015-11-24,Ocular Therapeutix™ Begins Enrollment In Its Second Phase 3 Clinical Trial For DEXTENZA™ For The Treatment Of Allergic Conjunctivitis
2015-11-10,Ocular Therapeutix™ Reports Third Quarter 2015 Financial Results
2015-11-09,Ocular Therapeutix™ Expands Its Board Of Directors With The Election Of Industry Leader W. James O'Shea
2015-11-03,Ocular Therapeutix™ To Report Third Quarter 2015 Financial Results
2015-10-28,Ocular Therapeutix™ To Participate In Three Conferences In November 2015
2015-10-28,5 Biotech Stocks Under $10 Triggering Breakout Trades
2015-10-23,Ocular Therapeutix is Now Oversold (OCUL)
2015-10-22,Ocular TherapeutixTM Reports On Topline Results Of Phase 2b Glaucoma Clinical Trial
2015-10-22,Ocular Therapeutix™ Announces Topline Results Of Phase 3 Clinical Trial For DEXTENZA™ For The Treatment Of Allergic Conjunctivitis
2015-10-14,Ocular Therapeutix™ Begins Enrollment In Third Phase 3 Clinical Trial For DEXTENZA™ for The Treatment Of Post-Surgical Ocular Inflammation And Pain
2015-09-28,Ocular Therapeutix™ Submits New Drug Application To U.S. Food And Drug Administration For DEXTENZA® For The Treatment Of Post-Surgical Ocular Pain
2015-09-23,5 Stocks Insiders Love Right Now
2015-09-14,Ocular Therapeutix Expands Its Board Of Directors With The Appointment Of Renowned Retinal Specialist Jeffrey S. Heier, M.D.
2015-09-03,Ocular Therapeutix™ To Participate In Two Investor Conferences In September 2015
2015-08-26,Ratings Changes Today
2015-08-20,Commit To Purchase Ocular Therapeutix At $15, Earn 33.5% Annualized Using Options
2015-08-11,Oversold Conditions For Ocular Therapeutix (OCUL)
2015-08-10,Ocular Therapeutix™ Reports Second Quarter 2015 Financial Results
2015-08-03,Ocular Therapeutix™ To Report Second Quarter 2015 Financial Results
2015-07-14,Market News: Micron Technology, SeaSpine Holdings, Ocular Therapeutix
2015-07-02,RSI Alert: Ocular Therapeutix (OCUL) Now Oversold
2015-06-30,Ocular Therapeutix™ To Participate At The Cantor Fitzgerald Inaugural Healthcare Conference
2015-06-26,5 Stocks Ready for Breakouts
2015-06-16,Ocular Therapeutix™ Begins Enrollment In Phase 3 Clinical Trial For DEXTENZA™ For The Treatment Of Allergic Conjunctivitis
2015-06-04,Ocular Therapeutix, Inc. Announces Pricing Of Public Offering Of Common Stock
2015-06-02,Ocular Therapeutix, Inc. Announces Proposed Public Offering Of Common Stock
2015-05-15,Ocular TherapeutixTM Announces Plans To Proceed With An NDA Submission For OTX-DP For Treatment Of Post-Surgical Ocular Pain Indication; Reports First Quarter 2015 Financial Results
2015-05-06,Ocular Therapeutix™ To Report First Quarter 2015 Financial Results
2015-05-01,Ocular Therapeutix To Present Eight Posters Highlighting Its Sustained Release Hydrogel Platform Technology At The Association For Research In Vision And Ophthalmology Annual Meeting
2015-04-07,Ocular Therapeutix Enters Oversold Territory (OCUL)
2015-04-06,Ocular Therapeutix Eye-Pain Plug Flops Confirmatory Pivotal Trial
2015-04-06,Ocular Therapeutix™ Reports Topline Clinical Data For Its Second Phase 3 Clinical Trial Evaluating OTX-DP For The Treatment Of Post-Surgical Ocular Inflammation And Pain
2015-03-10,Ocular Therapeutix Eye-Pain Plug Benefits Still Unclear
2015-03-10,Ocular Therapeutix™ Reports Fourth Quarter And Full Year 2014 Financial Results
2015-03-10,Ocular Therapeutix™ Reports Positive Topline Clinical Data For The First Of Two Phase 3 Clinical Trials Evaluating OTX-DP For The Treatment Of Post-Surgical Ocular Inflammation And Pain
2015-03-03,Ocular Therapeutix™ To Report Fourth Quarter And Full Year 2014 Financial Results
2015-02-19,Ocular Therapeutix™ To Participate In Two Upcoming Investor Conferences
2015-02-05,14 IPOs You Wish You Bought in 2014 (and Made a Killing On)
2015-02-04,Ocular Therapeutix™ To Present At The 17th Annual BIO CEO & Investor Conference
2015-01-21,Ocular Therapeutix™ Enrolls First Patient In Phase 2 Clinical Trial For Sustained Release Dexamethasone For The Treatment Of Dry Eye Disease
2014-12-02,Ocular Therapeutix™ To Present At Oppenheimer 25th Annual Healthcare Conference
2014-11-12,Ocular Therapeutix™ Reports Third Quarter 2014 Financial Results
2014-11-12,Ocular Therapeutix™ Enrolls First Patients In Phase 2b Clinical Trial For Sustained Release Travoprost For The Treatment Of Glaucoma And Ocular Hypertension
2014-11-12,Ocular Therapeutix™ Announces Top-Line Results From Phase 2 Sustained Release Dexamethasone Trial For Allergic Conjunctivitis
2014-11-05,Ocular Therapeutix™ To Report Third Quarter 2014 Financial Results And Provide Business Updates On Wednesday, November 12, 2014
2014-10-31,Ocular Therapeutix™ To Participate In Two Investor Conferences In November 2014
2014-10-14,Ocular Therapeutix™ To Attend American Academy Of Ophthalmology Annual Meeting In Chicago, Illinois
2014-10-08,Ocular Therapeutix™ Completes Enrollment In Phase 3 Sustained Release Dexamethasone Trials For Post-Operative Inflammation And Pain
2014-09-16,Ocular Therapeutix To Present At The 21st Annual NewsMakers In The Biotech Industry Investment Conference On Friday, September 26
2014-09-03,Ocular Therapeutix To Present At Morgan Stanley 2014 Global Healthcare Conference
2014-08-28,Ocular Therapeutix Announces Second Quarter 2014 Financial Results
2014-08-19,Ocular Therapeutix Announces Exercise Of Over-Allotment Option
2014-07-30,Ocular Therapeutix Announces Closing Of Initial Public Offering
,
